دورية أكاديمية
Therapeutic Strategies to Overcome Fibrotic Barriers to Nanomedicine in the Pancreatic Tumor Microenvironment
| العنوان: | Therapeutic Strategies to Overcome Fibrotic Barriers to Nanomedicine in the Pancreatic Tumor Microenvironment |
|---|---|
| المؤلفون: | Tanaka, Hiroyoshi Y., Nakazawa, Takuya, Enomoto, Atsushi, Masamune, Atsushi, Kano, Mitsunobu R. |
| المصدر: | Cancers |
| بيانات النشر: | MDPI |
| سنة النشر: | 2023 |
| المجموعة: | Okayama University Scientific Achievement Repository / 岡山大学学術成果リポジトリ |
| مصطلحات موضوعية: | pancreatic cancer, tumor microenvironment, nanomedicine, fibrosis, extracellular matrix, fibroblast |
| الوصف: | Simple Summary Pancreatic cancer is difficult to treat. Novel treatment strategies are urgently needed to improve the survival rate, which is approximately 10% five years after diagnosis. The use of nanomedicines, which are formulated within a characteristic size range that favors its specific delivery to the diseased tissue, is being actively explored in cancer treatment. However, fibrosis (the abnormal accumulation of a cell type called fibroblasts and the fibrous protein network that they create) is characteristically seen in pancreatic cancer and hinders the delivery of nanomedicines into cancerous tissue. The decreased efficiency of delivery limits the therapeutic effects of nanomedicine in pancreatic cancer. We call this the "fibrotic barrier" to nanomedicine. To overcome the fibrotic barrier, we could target the fibrotic process and/or optimize the nanomedicine design. In this review, we give a detailed overview of strategies to overcome the fibrotic barriers in pancreatic cancer and highlight key gaps in our understanding. Pancreatic cancer is notorious for its dismal prognosis. The enhanced permeability and retention (EPR) effect theory posits that nanomedicines (therapeutics in the size range of approximately 10-200 nm) selectively accumulate in tumors. Nanomedicine has thus been suggested to be the "magic bullet"-both effective and safe-to treat pancreatic cancer. However, the densely fibrotic tumor microenvironment of pancreatic cancer impedes nanomedicine delivery. The EPR effect is thus insufficient to achieve a significant therapeutic effect. Intratumoral fibrosis is chiefly driven by aberrantly activated fibroblasts and the extracellular matrix (ECM) components secreted. Fibroblast and ECM abnormalities offer various potential targets for therapeutic intervention. In this review, we detail the diverse strategies being tested to overcome the fibrotic barriers to nanomedicine in pancreatic cancer. Strategies that target the fibrotic tissue/process are discussed first, which are followed by ... |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| تدمد: | 2072-6694 |
| العلاقة: | info:pmid/36765684; https://ousar.lib.okayama-u.ac.jp/files/public/6/64414/20230310115156984323/fulltext.pdfTest; https://ousar.lib.okayama-u.ac.jp/64414Test |
| الإتاحة: | https://doi.org/10.3390/cancers15030724Test https://ousar.lib.okayama-u.ac.jp/files/public/6/64414/20230310115156984323/fulltext.pdfTest https://ousar.lib.okayama-u.ac.jp/64414Test |
| حقوق: | © 2023 by the authors. |
| رقم الانضمام: | edsbas.E13189 |
| قاعدة البيانات: | BASE |
Full Text Finder | تدمد: | 20726694 |
|---|